Open AccessAntacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
Author(s) -
Michael Kreuter,
Paolo Spagnolo,
Wim Wuyts,
Elisabetta Renzoni,
Dirk Koschel,
Francesco Bonella,
Toby M. Maher,
Martin Kolb,
Derek Weycker,
Klaus-Uwe Kirchgässler,
Ulrich Costabel
Publication year - 2017
Publication title -
respiration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.264
H-Index - 81
eISSN - 1423-0356
pISSN - 0025-7931
DOI - 10.1159/000468546
Subject(s) - medicine , pirfenidone , idiopathic pulmonary fibrosis , gastroenterology , vital capacity , pulmonary function testing , adverse effect , lung , lung function , diffusing capacity
Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom